By Kristen Monaco
PHILADELPHIA — Treatment with sparsentan (Filspari) led to no significant differences in estimated glomerular filtration rate (eGFR) slope compared with irbesartan among patients with focal segmental glomerulosclerosis (FSGS), the phase III DUPLEX trial showed.
Read the full article in MedPage Today.
By Mitchel L. Zoler, PhD
French researchers have developed and validated a creatinine-based, race-free equation for calculating estimated glomerular filtration rate (eGFR) in people who have received a kidney transplant. It performed as well, or better, than three established eGFR equations, including the 2021 race-free equation now widely used in US practice.
“The new equation provides a more accurate estimation of kidney function” in kidney transplant recipients compared with prior equations, said Marc Raynaud, PhD, lead author of the report, which was recently published in BMJ. Read more in Medscape.
A new policy action now in effect means some Black kidney candidates will be eligible to receive waiting time modifications and increase their waiting times (and potentially their prioritization for transplant). Read more from UNOS.
Estimated glomerular filtration rate (eGFR) is the best marker of allograft function and is a predictor of allograft and patient survival among kidney transplant recipients. Measurement of true GFR is costly and time-consuming, while eGFR is a relatively inexpensive and efficient marker to track allograft function.
Read more in Nephrology Times.
“Removing race from estimated glomerular filtration rate (eGFR) equations would result in fewer Black patients being eligible for certain anticancer drugs, researchers have demonstrated.
Their analysis showed that for Black patients, removing race from the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation reduced median eGFR from 103 mL/min to 89 mL/min. In addition, removing the race factor doubled the percentage of black patients with an eGFR under 60 mL/min — a clinically relevant cut-off below which many drugs have recommended changes to dosage and eligibility, reported Thomas D. Nolin, PharmD, PhD, of the University of Pittsburgh School of Pharmacy, and colleagues.”
Learn more here.